Fangyuan Zhu

Fangyuan Zhu

Auto-generated profile, based on publicly available information

Fangyuan Zhu

Xixi Hospital of Hangzhou, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 October 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
JWJin Wu
Jin Wu
YLYiting Luo
Yiting Luo
YSYan Shen
Yan Shen
YHYuyao Hu
Yuyao Hu
FZFangyuan Zhu
Fangyuan Zhu
YLYingchao Liu
Yingchao Liu
Background: Traditional Chinese medicine (TCM) has the advantage of multi-component and multi-target, which becomes a hot spot in the treatment of numerous diseases. Shaoyao decoction (SYD) is a TCM prescription, which is mainly used to treat damp-heat dysentery clinically, with small side effects and low cost. However, its mechanism remains elusive. The purpose of this study is to explore the mechanism of SYD in the treatment of mice with ulcerative colitis (UC) induced by dextran sulfate sodium (DSS) through metabolomics and network pharmacology, and verify through molecular docking and immunohistochemistry, so as to provide a scientific basis for the role of SYD in the treatment of UC. Materials and Methods: Firstly, DSS-induced UC models were established and then untargeted metabolomics analysis of feces, livers, serum and urine was performed to determine biomarkers and metabolic pathways closely related to the role of SYD. Besides, network pharmacology was applied to screen the active components and UC-related targets, which was verified by molecular docking. Finally, metabonomics and network pharmacology were combined to draw the metabolite-pathway-target network and verified by immunohistochemistry. Results: Metabolomics results showed that a total of 61 differential metabolites were discovered in SYD-treated UC with 3 main metabolic pathways containing glycerophospholipid metabolism, sphingolipid metabolism and biosynthesis of unsaturated fatty acids, as well as 8 core targets involving STAT3, IL1B, IL6, IL2, AKT1, IL4, ICAM1 and CCND1. Molecular docking demonstrated that the first five targets had strong affinity with quercetin, wogonin, kaempferol and baicalein. Combined with metabolomics and network pharmacology, sphingolipid signaling pathway, PI3K/AKT-mTOR signaling pathway and S1P3 pathway were identified as the main pathways. Conclusion: SYD can effectively ameliorate various symptoms and alleviate intestinal mucosal damage and metabolic disorder in DSS induced UC mice. Its effect is mainly related to sphingolipid metabolism, PI3K/AKT-mTOR signaling pathway and S1P3 pathway.

22 December 2022 in Drug Design, Development and Therapy
Verified
Journal Article
Open access
PDF file
YLYiting Luo
Yiting Luo
JWJin Wu
Jin Wu
YLYingchao Liu
Yingchao Liu
YSYan Shen
Yan Shen
FZFangyuan Zhu
Fangyuan Zhu
YHYuyao Hu
Yuyao Hu
Purpose: Shaoyao decoction (SYD) is a traditional Chinese medicine used to treat ulcerative colitis (UC). The exact mechanism of action of SYD in UC treatment is still unclear. Here, we examined the therapeutic effects of SYD in mice with dextran sulfate sodium (DSS)-induced colitis and explored the underlying mechanism. Methods: The experimental group was divided into normal control, UC, and SYD treatment groups. The UC model of C57BL/6 mice was induced using 3% (w/v) DSS for 7 days. SYD was orally administered for 7 days. The proximal and distal colonic metabolic profiles were detected using quadrupole-time-of-flight mass spectrometry-based untargeted metabolomics. Results: SYD significantly increased weight, reduced disease activity index scores, and ameliorated colon length shortening and pathological damage in mice. In the distal colon, SYD increased the abundance of phosphatidic acid and lysophosphatidylethanolamine and decreased the abundance of lactosylceramide, erythrodiol 3-palmitate, and lysophosphatidylcholine. In the proximal colon, SYD increased the abundance of palmitic acid, cyclonormammein, monoacylglyceride, 13S-hydroxyoctadecadienoic acid, and ceanothine C and decreased the abundance of tetracosahexaenoic acid, phosphatidylserine, and diglyceride. Conclusion: Our findings revealed that SYD could alleviate UC by regulating metabolic dysfunction, which provides a reference for further studies on SYD.


21 December 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
YZYuan Fang Zhu
Yuan Fang Zhu
TLTing Yi Luo
Ting Yi Luo
JWJin Wu
Jin Wu
YCYa Jie Chen
Ya Jie Chen
CLChao Ying Liu
Chao Ying Liu
Objective: To explore the impact of IFX on intestinal ecological imbalance in UC and the role of gut microbiota in predicting the response of IFX. Result: The clinical study included 14 patients with moderate to severe active UC who received IFX intervention. Fecal samples of UC patients who reached early clinical remission status during the active phase, after the first IFX intervention, and at 14 weeks were collected for 16S rDNA gene testing and microbial community analysis. Animal research will establish a UC rat model using TNBS, inject it intraperitoneally with IFX, and collect fecal samples from rats for 16S rDNA gene detection and microbial community analysis. IFX can improve the ecological imbalance environment in the intestine, including Trichospira, Roseburia, Faecalis, Coprococcus, Veillonella, Dialister, Streptococcus in the Firmicutes phylum, Fusobacterium, a member of the Fusobacterium phylum, and Akkermansia, a member of the Akkermansia phylum, may be biomarkers for predicting the response of biological agents. Conclusion: The presence of certain bacterial communities, such as Faecalibacterium, can be regarded as markers of ecological imbalance and can predict the response of biological agents.